Skip to main content

Clinical governance

Clinical governance starts with explicit boundaries

PHARMORIS is intended to support authorised medicines operations without replacing clinical, pharmacy, governance or information governance judgement.

Discuss the governance approachRead the evidence boundary
Human decision requiredProceed only inside an evidenced and governed scope.
Current scope | No patient identifiable dataClinical boundary | No autonomous prescribingAdoption | Local approval remains adopter owned

Professional authority

The system supports a decision process. It does not make the decision.

Authorised professionals remain responsible for clinical, pharmacy, finance, procurement, governance and information governance judgement.

PHARMORIS is not a point of prescribing clinical decision support tool and is not presented as a medical device.

01

Triage

An authorised human decides whether a candidate signal should progress.

02

Review

The relevant governance body considers the evidence and local context.

03

Decision

An accountable person or body records the authorised outcome.

Responsibility map

Supplier controls and adopter approvals must not be conflated.

NEUVIOR is responsible for evidenced supplier controls within the product scope. Each adopter remains responsible for its local governance, information governance and implementation decisions.

01

Supplier

Evidence the product version, security controls, boundaries and operating documentation.

NEUVIOR scope
02

Adopter

Complete local assurance, governance, workflow approval and operational ownership.

Customer scope
03

Shared

Agree the evaluation scope, success measures, escalation route and evidence exchange.

Joint scope

No go conditions

Do not progress when the intended use exceeds the evidenced boundary.

A buyer facing release must stop if source claims exceed proof, authority is uncertain, critical security risks remain or local responsibilities are obscured.

Human decision requiredProceed only inside an evidenced and governed scope.
01

Unsupported clinical claim

Do not imply clinical efficacy, patient outcomes or professional approval without named evidence.

02

Unsafe authority

Do not permit synthetic, bypassable or client trusted role decisions.

03

Unclear intended use

Narrow or re architect when the workflow approaches a medical device or prescribing function.

Classified public record

Open the classified public record

ANALYSIS + EVIDENCE BOUNDARY

Read the argument. Verify the product separately.

Published analysis can explain why governance matters. It cannot evidence security, clinical authority, certification, product readiness or local approval. Use the dated NEUVIOR records for that.

  1. AI Ethics Now / University of Warwick IATLPodcast appearance

    AI and Accountability: When Does a Suggestion Become a Decision?

    Varun Sharma joins AI Ethics Now to examine false confidence, human responsibility and the point where AI assisted suggestions become accountable decisions.

    Hear where an AI suggestion becomes a decision
  2. TechRadar ProContributed opinion

    Five questions to test whether an AI stack is truly under your control

    In TechRadar Pro, Varun Sharma sets out five tests for enterprise AI control across provenance, infrastructure, legal authority and safe exit.

    Test provenance, control and safe exit
  3. NEUVIOR InsightsNEUVIOR analysis

    From pilot theatre to financial grip: how NHS CFOs should evaluate AI in medicines optimisation

    NHS finance leaders do not need another AI pitch. They need a disciplined way to decide whether a technology can release value within the financial rules they are already being held to.

    See how a finance leader should test an AI claim
Read the governance arguments

NEUVIOR Insights and After Publication reflections are company or founder analysis. Publisher records evidence publication, not endorsement, adoption, product readiness, savings or clinical outcomes.

Make the next step useful

Bring the problem that needs a clearer decision.

Tell us what is stuck, what decision you need to make and what a better outcome would change. We will connect you to the most relevant NEUVIOR, PHARMORIS, media or investor route.

Discuss the governance approachSpeak with NEUVIOR

QUESTIONS · ANSWERED DIRECTLY

The useful answers, in one place.

Browse every question
01What is NEUVIOR?

NEUVIOR is a pharmaceutical company registered in Scotland. It is building capabilities across medicines intelligence, governed technology and longer term development. PHARMORIS is its immediate product priority.

02What does NEUVIOR build today?

NEUVIOR is developing PHARMORIS, a human-governed medicines operations system in controlled, non-production development. It is intended to connect evidence, decisions, accountable work and value review. No independent TRL, deployment, customer adoption or clinical validation is claimed.

03What is PHARMORIS by NEUVIOR?

PHARMORIS is a configurable medicines operations system under controlled development. It is designed to help authorised teams progress medicine opportunities from evidence linked to its source, through an owned ActionCase, a human decision, delivery and review.

04Who founded NEUVIOR?

Varun Sharma is the Founder, CEO and CTO of NEUVIOR and leads the company and PHARMORIS product architecture.

05Where does NEUVIOR have a presence?

NEUVIOR works across Glasgow, London and Mumbai. Glasgow is the company origin and registered Scottish base. London supports commercial activity led by the founder. Mumbai supports market engagement in India and relationships across the pharmaceutical sector. These are different forms of presence. They do not imply three registered offices or regulated facilities.